Halozyme Therapeutics (HALO) Shares Outstanding (Diluted Average) (2016 - 2025)
Halozyme Therapeutics (HALO) has disclosed Shares Outstanding (Diluted Average) for 14 consecutive years, with $123.9 million as the latest value for Q4 2025.
- On a quarterly basis, Shares Outstanding (Diluted Average) fell 4.27% to $123.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $123.9 million, a 4.27% decrease, with the full-year FY2025 number at $123.9 million, down 4.27% from a year prior.
- Shares Outstanding (Diluted Average) was $123.9 million for Q4 2025 at Halozyme Therapeutics, roughly flat from $124.4 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $148.5 million in Q1 2021 to a low of $123.9 million in Q4 2025.
- A 5-year average of $135.8 million and a median of $135.0 million in 2023 define the central range for Shares Outstanding (Diluted Average).
- Peak YoY movement for Shares Outstanding (Diluted Average): grew 8.28% in 2021, then dropped 6.54% in 2024.
- Halozyme Therapeutics' Shares Outstanding (Diluted Average) stood at $146.8 million in 2021, then fell by 4.22% to $140.6 million in 2022, then dropped by 4.56% to $134.2 million in 2023, then decreased by 3.56% to $129.4 million in 2024, then decreased by 4.27% to $123.9 million in 2025.
- Per Business Quant, the three most recent readings for HALO's Shares Outstanding (Diluted Average) are $123.9 million (Q4 2025), $124.4 million (Q3 2025), and $125.5 million (Q2 2025).